Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors

Cancers(2023)10.3390/cancers16010091Source: DataRank Database

First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors is a research paper published in Cancers (2023). On theSindex it has a DataRank of 0. It has been cited 11 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access11 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: goldTopics (8)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (19)

Jodi Kagihara ORCID,Bradley R. Corr ORCID,S. Lindsey Davis ORCID,Christopher H. Lieu ORCID,Sunnie S. Kim ORCID

Live enrichment

PubMed:38201519 PMC:PMC10778198

National Institutes of Health (NIH) and the National Cancer Institute (NCI)

Grant: 5P30CA046934-25

PROTOCOL SPECIFIC RESEARCH

National Institutes of Health (NIH) and the National Cancer Institute (NCI)

Grant: RR160093

NCI NIH HHS

Grant: P30 CA046934

OnKure, Inc.

goldLicense: cc-by

publisherhttps://www.mdpi.com/2072-6694/16/1/91/pdf?version=1703327621

publisherhttps://www.mdpi.com/2072-6694/16/1/91/pdf

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10778198/pdf/cancers-16-00091.pdf

Europe_PMChttps://europepmc.org/articles/PMC10778198

Europe_PMChttps://europepmc.org/articles/PMC10778198?pdf=render

Fields of Study

0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

Solid TumorsHdac InhibitorsMek InhibitorsPhase I Clinical TrialArticle

Sustainable Development Goals

SDG 3: 3. Good health

First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors

FAIR Checklist

Authors (19)

Funding (4 grants)

Open Access

Topics

Annotations (Europe PMC)